A publication from Acta Pharmaceutica Sinica B discusses the structure-based development of potent and selective type-II kinase inhibitors of RIPK1. Receptor-interacting serine/threonine-protein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback